Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

An important motivation for the use of nanomaterials and nanoarchitectures in cancer
therapy emanates from the widespread emergence of drug resistance. Although doxorubicin …

Human DNA topoisomerase II is an important target in anticancer therapy. Despite the
clinical success of drugs that target topoisomerase II, the development of resistant cancer …

Doxorubicin (Dox) is an effective antineoplastic agent used to treat cancers, but its use is
limited as Dox induces adverse cardiotoxic effects. Dox-induced cardiotoxicity (DIC) can …

Reactive oxygen species play crucial role in biological homeostasis and pathogenesis of
human diseases including cancer. In this line, now it has become evident that ROS …

Cardiotoxicity is the main concern for long‐term use of the doxorubicin (DOX). Reactive
oxygen species (ROS) generation leads to oxidative stress that significantly contributes to …

Curcumin, a natural polyphenolic and yellow pigment obtained from the spice turmeric, has
strong antioxidative, anti‐inflammatory, and antibacterial properties. Due to these properties …

Background Doxorubicin is one of the most commonly prescribed and time-tested anticancer
drugs. Although being considered as a first line drug in different types of cancers, the two …

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field
of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin …

Cancer is among the leading causes of death worldwide and it is estimated that in 2040
more than 29 million people will be diagnosed with some type of cancer. The most prevalent …